Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Icecure Medical ( (ICCM) ) has provided an announcement.
On March 25, 2026, IceCure Medical reported positive five-year top-line results from its ICESECRET clinical trial evaluating the ProSense® cryoablation system for small renal masses in kidney cancer patients. At a median follow-up of four years, 83.9% of the 112 evaluated patients were recurrence-free, with a subgroup of patients with tumors ≤3 cm and no prior kidney cancer achieving an 89.4% recurrence-free rate.
The study, conducted at two centers in Israel with 114 enrolled patients and 138 lesions, supports ProSense® as a minimally invasive, nephron-sparing alternative to surgery for localized kidney tumors in markets where it is already approved, including the U.S. and Europe. IceCure plans to present a full analysis of the data at the European Conference on Interventional Oncology 2026 in Basel, potentially strengthening physician confidence and commercial adoption amid rising global kidney cancer incidence and unmet treatment needs.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.61 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses, significant cash burn, and shrinking equity), with limited valuation support due to negative earnings. Offsetting this, the latest earnings call points to improving commercial prospects and multiple adoption catalysts (FDA clearance, society endorsement, planned salesforce expansion), while technicals remain weak/neutral.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is an Israeli medical device company that develops and markets minimally invasive, liquid-nitrogen-based cryoablation systems for destroying benign and cancerous tumors. Its flagship ProSense® system is cleared in the U.S., Europe, Asia and other key markets for indications including breast, kidney, bone, lung and other tumors, positioning the company in the interventional oncology space.
Average Trading Volume: 291,048
Technical Sentiment Signal: Sell
Current Market Cap: $43.79M
For an in-depth examination of ICCM stock, go to TipRanks’ Overview page.